<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33891869</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition.</ArticleTitle><Pagination><StartPage>2213</StartPage><EndPage>2227</EndPage><MedlinePgn>2213-2227</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2021.03.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(21)00160-0</ELocationID><Abstract><AbstractText>Neuromuscular junctions (NMJs) ensure communication between motor neurons (MNs) and muscle; however, in MN disorders, such as amyotrophic lateral sclerosis (ALS), NMJs degenerate resulting in muscle atrophy. The aim of this study was to establish a versatile and reproducible in&#xa0;vitro model of a human motor unit to investigate the effects of ALS-causing mutations. Therefore, we generated a co-culture of human induced pluripotent stem cell (iPSC)-derived MNs and human primary mesoangioblast-derived myotubes in microfluidic devices. A chemotactic and volumetric gradient facilitated the growth of MN neurites through microgrooves resulting in the interaction with myotubes and the formation of NMJs. We observed that ALS-causing FUS mutations resulted in reduced neurite outgrowth as well as an impaired neurite regrowth upon axotomy. NMJ numbers were likewise reduced in the FUS-ALS model. Interestingly, the selective HDAC6 inhibitor, Tubastatin A, improved the neurite outgrowth, regrowth, and NMJ morphology, prompting HDAC6 inhibition as a potential therapeutic strategy for ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stoklund Dittlau</LastName><ForeName>Katarina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute, Leuven, Belgium; VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krasnow</LastName><ForeName>Emily N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute, Leuven, Belgium; VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute, Leuven, Belgium; VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandoorne</LastName><ForeName>Tijs</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute, Leuven, Belgium; VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baatsen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Research Group Molecular Neurobiology, Leuven, Belgium; KU Leuven - University of Leuven, VIB Bio Imaging Core, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerstens</LastName><ForeName>Axelle</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Research Group Molecular Neurobiology, Leuven, Belgium; KU Leuven - University of Leuven, VIB Bio Imaging Core, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacomazzi</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Development and Regeneration, Stem Cell and Developmental Biology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavie</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Research Group Molecular Neurobiology, Leuven, Belgium; KU Leuven - University of Leuven, VIB Bio Imaging Core, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossaert</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute, Leuven, Belgium; VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckers</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute, Leuven, Belgium; VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampaolesi</LastName><ForeName>Maurilio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Development and Regeneration, Stem Cell and Developmental Biology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute, Leuven, Belgium; VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium; University Hospitals Leuven, Department of Neurology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Den Bosch</LastName><ForeName>Ludo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute, Leuven, Belgium; VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium. Electronic address: ludo.vandenbosch@kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018171">Agrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007797">Laminin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="C433811">HDAC6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="D000073864">Histone Deacetylase 6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018171" MajorTopicYN="N">Agrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073864" MajorTopicYN="N">Histone Deacetylase 6</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056656" MajorTopicYN="Y">Lab-On-A-Chip Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007797" MajorTopicYN="N">Laminin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046210" MajorTopicYN="N">Microfluidic Analytical Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018485" MajorTopicYN="N">Muscle Fibers, Skeletal</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071446" MajorTopicYN="N">Neuronal Outgrowth</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">HDAC6</Keyword><Keyword MajorTopicYN="N">Tubastatin A</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">microfluidic device</Keyword><Keyword MajorTopicYN="N">neurite outgrowth</Keyword><Keyword MajorTopicYN="N">neurite regrowth</Keyword><Keyword MajorTopicYN="N">neuromuscular junction</Keyword></KeywordList><CoiStatement>L.V.D.B. has a patent on the use of HDAC inhibitors in Charcot-Marie-Tooth disease (US-2013227717-A1), is scientific co-founder of Augustine Therapeutics and a member of its scientific advisory board. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33891869</ArticleId><ArticleId IdType="pmc">PMC8452598</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2021.03.029</ArticleId><ArticleId IdType="pii">S2213-6711(21)00160-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Afshar Bakooshli M., Lippmann E.S., Mulcahy B., Iyer N., Nguyen C.T., Tung K., Stewart B.A., van den Dorpel H., Fuehrmann T., Shoichet M., et al. A 3D culture model of innervated human skeletal muscle enables studies of the adult neuromuscular junction. eLife. 2019;8:e44530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6516829</ArticleId><ArticleId IdType="pubmed">31084710</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama T., Suzuki N., Ishikawa M., Fujimori K., Sone T., Kawada J., Funayama R., Fujishima F., Mitsuzawa S., Ikeda K., et al. Aberrant axon branching via Fos-B dysregulation in FUS-ALS motor neurons. EBioMedicine. 2019;45:362&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642224</ArticleId><ArticleId IdType="pubmed">31262712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmann J., Goswami R.Y., Girardo S., Rein N., Hosseinzadeh Z., Hicks M.R., Busskamp V., Pyle A.D., Werner C., Sterneckert J. A customizable microfluidic platform for medium-throughput modeling of neuromuscular circuits. Biomaterials. 2019;225:119537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294901</ArticleId><ArticleId IdType="pubmed">31614290</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoy V., Van Helleputte L., Prior R., d&#x2019;Ydewalle C., Haeck W., Geens N., Scheveneels W., Schevenels B., Cader M.Z., Talbot K., et al. HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. Brain. 2018;141:673&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837793</ArticleId><ArticleId IdType="pubmed">29415205</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoy V., Vanden Berghe P., Jarpe M., Van Damme P., Robberecht W., Van Den Bosch L. Development of improved HDAC6 inhibitors as pharmacological therapy for axonal Charcot-Marie-Tooth disease. Neurotherapeutics. 2017;14:417&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5398982</ArticleId><ArticleId IdType="pubmed">27957719</ArticleId></ArticleIdList></Reference><Reference><Citation>Burden S.J., Huijbers M.G., Remedio L. Fundamental molecules and mechanisms for forming and maintaining neuromuscular synapses. Int. J. Mol. Sci. 2018;19:490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5855712</ArticleId><ArticleId IdType="pubmed">29415504</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkin D.J., Kim J.E., Gu M., Kaufman S.J. Laminin and alpha 7 beta 1 integrin regulate agrin-induced clustering of acetylcholine receptors. J.&#xa0;Cell Sci. 2000;113:2877&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pubmed">10910772</ArticleId></ArticleIdList></Reference><Reference><Citation>Campenot R.B. Local control of neurite development by nerve growth factor. Proc. Natl. Acad. Sci. U S A. 1977;74:4516&#x2013;4519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC431975</ArticleId><ArticleId IdType="pubmed">270699</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Ydewalle C., Krishnan J., Chiheb D.M., Van Damme P., Irobi J., Kozikowski A.P., Vanden Berghe P., Timmerman V., Robberecht W., Van Den Bosch L. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat. Med. 2011;17:968&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">21785432</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M., Melamed E., Offen D. The &#x201c;dying-back&#x201d; phenomenon of motor neurons in ALS. J.&#xa0;Mol. Neurosci. 2010;43:470&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jongh R., Spijkers X.M., Pasteuning-Vuhman S., Vulto P., Pasterkamp R.J. Neuromuscular junction-on-a-chip: ALS disease modeling and read-out development in microfluidic devices. J.&#xa0;Neurochem. 2021 doi: 10.1111/jnc.15289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15289</ArticleId><ArticleId IdType="pubmed">33382092</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellavalle A., Sampaolesi M., Tonlorenzi R., Tagliafico E., Sacchetti B., Perani L., Innocenzi A., Galvez B.G., Messina G., Morosetti R., et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 2007;9:255&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">17293855</ArticleId></ArticleIdList></Reference><Reference><Citation>Demestre M., Orth M., F&#xf6;hr K.J., Achberger K., Ludolph A.C., Liebau S., Boeckers T.M. Formation and characterisation of neuromuscular junctions between hiPSC derived motoneurons and myotubes. Stem Cell Res. 2015;15:328&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">26255853</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazal R., Boeynaems S., Swijsen A., De Decker M., Fumagalli L., Moisse M., Vanneste J., Guo W., Boon R., Vercruysse T., et al. HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO J. 2021;40:e106177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013789</ArticleId><ArticleId IdType="pubmed">33694180</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 2004;185:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K., Ishikawa M., Otomo A., Atsuta N., Nakamura R., Akiyama T., Hadano S., Aoki M., Saya H., Sobue G., et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Greek R., Hansen L.A. Questions regarding the predictive value of one evolved complex adaptive system for a second: exemplified by the SOD1 mouse. Prog. Biophys. Mol. Biol. 2013;113:231&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">23791779</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordov&#xe1;s L., Patel A., Welters M., Vanwelden T., et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Stoklund Dittlau K., Van Den Bosch L. Axonal transport defects and neurodegeneration: molecular mechanisms and therapeutic implications. Semin. Cell Dev. Biol. 2019;99:133&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">31542222</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X., Gonzalez M., Stancescu M., Vandenburgh H.H., Hickman J.J. Neuromuscular junction formation between human stem cell-derived motoneurons and human skeletal muscle in a defined system. Biomaterials. 2011;32:9602&#x2013;9611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200565</ArticleId><ArticleId IdType="pubmed">21944471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiwlawat N., Lynch E., Jeffrey J., Van Dyke J.M., Suzuki M. Current progress and challenges for skeletal muscle differentiation from human pluripotent stem cells using transgene-free approaches. Stem Cells Int. 2018;11:6241681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5924987</ArticleId><ArticleId IdType="pubmed">29760730</ArticleId></ArticleIdList></Reference><Reference><Citation>Jocher G., Mannschatz S.H., Offterdinger M., Schweigreiter R. Microfluidics of small-population neurons allows for a precise quantification of the peripheral axonal growth state. Front. Cell. Neurosci. 2018;12:166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013724</ArticleId><ArticleId IdType="pubmed">29962939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones R.A., Harrison C., Eaton S.L., Llavero Hurtado M., Graham L.C., Alkhammash L., Oladiran O.A., Gale A., Lamont D.J., Simpson H., et al. Cellular and molecular anatomy of the human neuromuscular junction. Cell Rep. 2017;21:2348&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5723673</ArticleId><ArticleId IdType="pubmed">29186674</ArticleId></ArticleIdList></Reference><Reference><Citation>Krukowski K., Ma J., Golonzhka O., Laumet G.O., Gutti T., Van Duzer J.H., Mazitschek R., Jarpe M.B., Heijnen C.J., Kavelaars A. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain. 2017;158:1126&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435512</ArticleId><ArticleId IdType="pubmed">28267067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer T.T., Misgeld T., Lichtman J.W., Sanes J.R. Nerve-independent formation of a topologically complex postsynaptic apparatus. J.&#xa0;Cell Biol. 2004;164:1077&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172060</ArticleId><ArticleId IdType="pubmed">15037598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.Y., Yoshida M., Li L.T., Ikenaka A., Oshima S., Nakagawa K., Sakurai H., Matsui E., Nakahata T., Saito M.K. iPSC-derived functional human neuromuscular junctions model the pathophysiology of neuromuscular diseases. JCI Insight. 2019;4:e124299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6795289</ArticleId><ArticleId IdType="pubmed">31534050</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao C.X., Wen X., Jin S., Zhang Y.Q. Increased acetylation of microtubules rescues human tau-induced microtubule defects and neuromuscular junction abnormalities in Drosophila. Dis. Model. Mech. 2017;10:1245&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5665452</ArticleId><ArticleId IdType="pubmed">28819043</ArticleId></ArticleIdList></Reference><Reference><Citation>Martineau &#xc9;., Di Polo A., Vande Velde C., Robitaille R. Dynamic neuromuscular remodeling precedes motor-unit loss in a mouse model of ALS. eLife. 2018;7:e41973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234026</ArticleId><ArticleId IdType="pubmed">30320556</ArticleId></ArticleIdList></Reference><Reference><Citation>Maury Y., C&#xf4;me J., Piskorowski R.A., Salah-Mohellibi N., Chevaleyre V., Peschanski M., Martinat C., Nedelec S. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat. Biotechnol. 2015;33:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">25383599</ArticleId></ArticleIdList></Reference><Reference><Citation>Millet L.J., Gillette M.U. New perspectives on neuronal development via microfluidic environments. Trends Neurosci. 2012;35:752&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508261</ArticleId><ArticleId IdType="pubmed">23031246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills R., Taylor-Weiner H., Correia J.C., Agudelo L.Z., Allodi I., Kolonelou C., Martinez-Redondo V., Ferreira D.M.S., Nichterwitz S., Comley L.H., et al. Neurturin is a PGC-1&#x3b1;1-controlled myokine that promotes motor neuron recruitment and neuromuscular junction formation. Mol. Metab. 2018;7:12&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784328</ArticleId><ArticleId IdType="pubmed">29157948</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice J.R., Gregory-Evans C.Y., Shaw C.A. Animal models of amyotrophic lateral sclerosis: a comparison of model validity. Neural Regen. Res. 2018;13:2050&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray L.M., Talbot K., Gillingwater T.H. Neuromuscular synaptic vulnerability in motor neuron disease: amyotrophic lateral sclerosis and spinal muscular atrophy. Neuropathol. Appl. Neurobiol. 2010;36:133&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">20202121</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair G., Carew J.D., Usher S., Lu D., Hu X.P., Benatar M. Diffusion tensor imaging reveals regional differences in the cervical spinal cord in amyotrophic lateral sclerosis. Neuroimage. 2010;53:576&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">20600964</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M., Pal A., Goswami A., Lojewski X., Japtok J., Vehlow A., Naujock M., G&#xfc;nther R., Jin M., Stanslowsky N., et al. Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat. Commun. 2018;9:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5780468</ArticleId><ArticleId IdType="pubmed">29362359</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijssen J., Aguila J., Hoogstraaten R., Kee N., Hedlund E. Axon-seq decodes the motor axon transcriptome and its modulation in response to ALS. Stem Cell Reports. 2018;11:1565&#x2013;1578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6294264</ArticleId><ArticleId IdType="pubmed">30540963</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki T., Sivathanu V., Kamm R.D. Engineered 3D vascular and neuronal networks in a microfluidic platform. Sci. Rep. 2018;8:5168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5979969</ArticleId><ArticleId IdType="pubmed">29581463</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki T., Uzel S.G.M., Kamm R.D. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Sci. Adv. 2018;4:eaat5847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6179377</ArticleId><ArticleId IdType="pubmed">30324134</ArticleId></ArticleIdList></Reference><Reference><Citation>Osseni A., Ravel-chapuis A., Thomas J., Gache V., Schaeffer L., Jasmin B.J. HDAC6 regulates microtubule stability and clustering of AChRs at neuromuscular junctions. JCB. 2020;219:e201901099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7401804</ArticleId><ArticleId IdType="pubmed">32697819</ArticleId></ArticleIdList></Reference><Reference><Citation>Plomp J.J. In: Myasthenia Gravis and Related Disorders. Kaminski H.J., Kusner L.L., editors. Springer International Publishing; 2018. Neuromuscular junction physiology and pathophysiology; pp. 1&#x2013;12.</Citation></Reference><Reference><Citation>Prior R., Van Helleputte L., Klingl Y.E., Van Den Bosch L. HDAC6 as a potential therapeutic Target for peripheral nerve disorders. Expert Opin. Ther. Targets. 2018;22:993&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">30360671</ArticleId></ArticleIdList></Reference><Reference><Citation>Puttonen K.A., Ruponen M., Naumenko N., Hovatta O.H., Tavi P., Koistinaho J. Generation of functional neuromuscular junctions from human pluripotent stem cell lines. Front. Cell. Neurosci. 2015;9:473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672046</ArticleId><ArticleId IdType="pubmed">26696831</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossaert E., Van Den Bosch L. HDAC6 inhibitors: translating genetic and molecular insights into a therapy for axonal CMT. Brain Res. 2020;1733:146692.</Citation><ArticleIdList><ArticleId IdType="pubmed">32006555</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossaert E., Pollari E., Jaspers T., Van Helleputte L., Jarpe M., Van Damme P., De Bock K., Moisse M., Van Den Bosch L. Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. Acta Neuropathol. Commun. 2019;7:107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6612190</ArticleId><ArticleId IdType="pubmed">31277703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotini A., Mart&#xed;nez-Sarr&#xe0; E., Duelen R., Costamagna D., Di Filippo E.S., Giacomazzi G., Grosemans H., Fulle S., Sampaolesi M. Aging affects the in&#xa0;vivo regenerative potential of human mesoangioblasts. Aging Cell. 2018;17:e12714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5847873</ArticleId><ArticleId IdType="pubmed">29397577</ArticleId></ArticleIdList></Reference><Reference><Citation>Santhanam N., Kumanchik L., Guo X., Sommerhage F., Cai Y., Jackson M., Martin C., Saad G., McAleer C.W., Wang Y., et al. Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics. Biomaterials. 2018;166:64&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866791</ArticleId><ArticleId IdType="pubmed">29547745</ArticleId></ArticleIdList></Reference><Reference><Citation>So E., Mitchell J.C., Memmi C., Chennell G., Vizcay-Barrena G., Allison L., Shaw C.E., Vance C. Mitochondrial abnormalities and disruption of the neuromuscular junction precede the clinical phenotype and motor neuron loss in hFUSWT transgenic mice. Hum. Mol. Genet. 2018;27:463&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886082</ArticleId><ArticleId IdType="pubmed">29194538</ArticleId></ArticleIdList></Reference><Reference><Citation>Southam K.A., King A.E., Blizzard C.A., McCormack G.H., Dickson T.C. Microfluidic primary culture model of the lower motor neuron-neuromuscular junction circuit. J.&#xa0;Neurosci. Methods. 2013;218:164&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774648</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallon C., Russell K.A., Sakhalkar S., Andrapallayal N., Farah M.H. Length-dependent axo-terminal degeneration at the neuromuscular synapses of type II muscle in SOD1 mice. Neuroscience. 2016;312:179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691388</ArticleId><ArticleId IdType="pubmed">26592719</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor A.M., Blurton-Jones M., Rhee S.W., Cribbs D.H., Cotman C.W., Jeon N.L. A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat. Methods. 2005;2:599&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1558906</ArticleId><ArticleId IdType="pubmed">16094385</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonlorenzi R., Dellavalle A., Schnapp E., Cossu G., Sampaolesi M. Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues. Curr. Protoc. Stem Cell Biol. 2007;2:2B.1.</Citation><ArticleIdList><ArticleId IdType="pubmed">18785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack G.E., Luisier R., Taha D.M., Neeves J., Modic M., Mitchell J.S., Meyer I., Greensmith L., Newcombe J., Ule J., et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain. 2019;142:2572&#x2013;2580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>Umbach J.A., Adams K.L., Gundersen C.B., Novitch B.G. Functional neuromuscular junctions formed by embryonic stem cell-derived motor neurons. PLoS One. 2012;7:e36049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3344836</ArticleId><ArticleId IdType="pubmed">22574134</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Helleputte L., Kater M., Cook D.P., Eykens C., Rossaert E., Haeck W., Jaspers T., Geens N., Vanden Berghe P., Gysemans C., et al. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. Neurobiol. Dis. 2018;111:59&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">29197621</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T., Veys K., Guo W., Sicart A., Vints K., Swijsen A., Moisse M., Eelen G., Gounko N.V., Fumagalli L., et al. Differentiation but not ALS mutations in FUS rewires motor neuron metabolism. Nat. Commun. 2019;10:4147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742665</ArticleId><ArticleId IdType="pubmed">31515480</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.K., Spiller K.J., Ge G., Zheng A., Xu Y., Zhou M., Tripathy K., Kwong L.K., Trojanowski J.Q., Lee V.M.Y. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130:643&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Guo W., Mitra J., Hegde P.M., Vandoorne T., Eckelmann B.J., Mitra S., Tomkinson A.E., Van Den Bosch L., Hegde M.L. Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in amyotrophic lateral sclerosis. Nat. Commun. 2018;9:3683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6134028</ArticleId><ArticleId IdType="pubmed">30206235</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahavi E.E., Ionescu A., Gluska S., Gradus T., Ben-Yaakov K., Perlson E. A compartmentalized microfluidic neuromuscular co-culture system reveals spatial aspects of GDNF functions. J.&#xa0;Cell Sci. 2015;128:1241&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359927</ArticleId><ArticleId IdType="pubmed">25632161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B.G.X., Quigley A.F., Bourke J.L., Nowell C.J., Myers D.E., Choong P.F.M., Kapsa R.M.I. Combination of agrin and laminin increase acetylcholine receptor clustering and enhance functional neuromuscular junction formation in&#xa0;vitro. Dev. Neurobiol. 2016;76:551&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">26251299</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>